Please login to the form below
FDA approves 14 generic copies of GSK's Coreg
The FDA allows 14 generic manufacturers to sell first generic versions of GlaxoSmithKline's blood pressure drug Coreg in the US
The FDA has given 14 generic manufacturers permission to sell the first generic versions of GlaxoSmithKline's (GSK) blood pressure drug Coreg (carvedilol) on the US market.
The agency stated on 5 September 2007 that the companies, which included Caraco Pharmaceutical, Mylan, Ranbaxy and Watson, could sell generic versions of Coreg in strengths of 3.125 mg, 6.25 mg, 12.5 mg and 25 mg.
Coregis is approved in the US to treat high blood pressure, mild-to-severe chronic heart failure and left ventricular dysfunction following a heart attack.
GSK sells a newer, daily reformulation of the drug called Coreg CR, which is patent protected until 2023, according to the UK-based firm.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
- Novartis and smartpatient launch app experience for wet AMD patients
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Pfizer, Mylan move ahead with generics merger and spin-out
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Chief investigator of Oxford Vaccine Group says data could be released before Christmas
- CureVac reveals early data for mRNA-based COVID-19 vaccine candidate
- Laurence Bannister joins Lucid Group as its new Chief Commercial Officer
- AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%
- UK could approve Pfizer’s COVID-19 vaccine this week
- Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval
- Power to the patient: digital innovation supporting patients with chronic diseases
- New from the PhRMA: Diversity in clinical trials principles summarised
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- New from the PhRMA: Diversity in clinical trials principles summarised
- In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
- New from the FDA: Diversity in clinical trials guidance summarised
- In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
- 5 steps to effective clinical trial branding
- When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...
Quick links
Infographics
